Michael A Nauck Selected Research

dulaglutide

1/2024	Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
10/2020	The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
10/2020	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
12/2019	MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
11/2018	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
1/2017	Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael A Nauck Research Topics

Disease

117	Type 2 Diabetes Mellitus (MODY) 04/2024 - 03/2002
25	Body Weight (Weight, Body) 01/2024 - 04/2002
16	Weight Loss (Weight Reduction) 10/2023 - 09/2003
16	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 03/2002
14	Myocardial Infarction 01/2024 - 10/2005
10	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2023 - 08/2015
9	Pancreatitis 01/2020 - 07/2013
9	Weight Gain 09/2017 - 04/2002
8	Stroke (Strokes) 01/2024 - 01/2016
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 11/2013
8	Obesity 01/2023 - 04/2002
8	Nausea 01/2022 - 06/2005
7	Heart Failure 12/2022 - 01/2016
7	Insulin Resistance 01/2022 - 06/2008
6	Hyperglycemia 10/2023 - 12/2004
6	Vomiting 01/2022 - 06/2005
5	Glucose Intolerance 05/2020 - 11/2003
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 07/2013
4	Neoplasms (Cancer) 01/2020 - 05/2007
3	Inflammation (Inflammations) 01/2022 - 03/2004
3	Diabetes Mellitus 01/2020 - 09/2009
3	Chronic Pancreatitis 01/2020 - 07/2013
3	Acute Coronary Syndrome 01/2018 - 07/2002
2	Albuminuria 01/2023 - 01/2022
2	Constipation 01/2022 - 10/2020
2	Chronic Renal Insufficiency 01/2022 - 03/2004
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 08/2015
2	COVID-19 01/2021 - 12/2020
2	Peripheral Arterial Disease 01/2019 - 01/2018
2	Injection Site Reaction 02/2016 - 04/2014
2	Critical Illness (Critically Ill) 01/2015 - 03/2004
2	Infections 01/2014 - 09/2011
2	Urinary Tract Infections (Urinary Tract Infection) 01/2014 - 09/2011
1	Chronic Disease (Chronic Diseases) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Fatty Liver 01/2022
1	Diabetes Complications 01/2021
1	Vascular Diseases (Vascular Disease) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Diarrhea 10/2020
1	Dyspepsia (Indigestion) 10/2020
1	Amyloid Plaque 01/2020
1	Gastroesophageal Reflux (GERD) 01/2020

Drug/Important Bio-Agent (IBA)

66	Glucose (Dextrose)FDA LinkGeneric 10/2023 - 03/2002
55	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2024 - 03/2002
45	Insulin (Novolin)FDA Link 10/2023 - 05/2003
34	IncretinsIBA 10/2023 - 03/2004
29	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2024 - 05/2006
29	Liraglutide FDA Link 01/2022 - 06/2005
17	Glucagon-Like Peptide-1 ReceptorIBA 01/2024 - 10/2014
17	Metformin (Glucophage)FDA LinkGeneric 01/2023 - 07/2009
16	Hormones (Hormone)IBA 10/2023 - 03/2002
12	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2023 - 11/2006
11	Peptides (Polypeptides)IBA 10/2023 - 04/2004
10	Hypoglycemic Agents (Hypoglycemics)IBA 01/2023 - 06/2008
10	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2022 - 01/2003
10	semaglutideIBA 01/2022 - 02/2016
10	Sitagliptin Phosphate (Januvia)FDA Link 12/2020 - 11/2006
9	tirzepatideIBA 01/2024 - 11/2018
9	Exenatide (Byetta)FDA Link 01/2021 - 06/2005
8	Glucagon (Glukagon)FDA Link 01/2022 - 03/2002
7	Blood Glucose (Blood Sugar)IBA 01/2024 - 03/2004
6	dulaglutideIBA 01/2024 - 01/2017
6	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2024 - 09/2011
5	omega-Chloroacetophenone (Mace)IBA 01/2024 - 01/2019
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2023 - 03/2004
5	lixisenatideIBA 01/2020 - 01/2017
5	Insulin Glargine (Lantus)FDA Link 01/2020 - 07/2010
5	VildagliptinIBA 11/2016 - 11/2006
4	Sodium-Glucose Transport ProteinsIBA 01/2024 - 09/2011
4	rGLP-1 proteinIBA 12/2019 - 04/2014
4	C-PeptideIBA 02/2016 - 05/2003
4	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2016 - 03/2004
3	SodiumIBA 01/2023 - 01/2021
3	Amylases FDA Link 01/2017 - 11/2003
2	gastric inhibitory polypeptide receptorIBA 10/2023 - 12/2004
2	glimepiride (Amarel)FDA LinkGeneric 01/2023 - 09/2017
2	LipidsIBA 01/2023 - 12/2004
2	AcidsIBA 11/2022 - 01/2020
2	CarbohydratesIBA 02/2022 - 01/2017
2	octanoic acid (caprylic acid)IBA 01/2021 - 06/2003
2	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2020 - 01/2006
2	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2020 - 11/2016
2	Lipase (Acid Lipase)FDA Link 01/2017 - 11/2014
2	EnzymesIBA 01/2017 - 07/2010
2	Therapeutic UsesIBA 01/2016 - 07/2002
2	taspoglutideIBA 09/2013 - 07/2009
2	ProinsulinIBA 12/2012 - 10/2010
1	LC15-0444IBA 01/2023
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	LinagliptinIBA 01/2022
1	CreatinineIBA 01/2020

Therapy/Procedure

37	Therapeutics 04/2024 - 04/2004
7	Glycemic Control 10/2023 - 06/2008
5	Injections 01/2023 - 06/2005
3	Bariatric Surgery 01/2023 - 01/2016
3	Aftercare (After-Treatment) 01/2022 - 04/2011
3	Intravenous Infusions 01/2017 - 12/2003
2	Drug Therapy (Chemotherapy) 05/2007 - 04/2002
1	Subcutaneous Injections 01/2024